StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CELCVery BullishEarningsnews
High materiality9/10

Celcuity wins FDA approval, NCCN backing; near-term launch upside

Aug 13, 2026, 4:19 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Regulatory clearance, strong guideline endorsement, and positive pivotal-trial data create tangible near-term upside; projected late-2026 revenue ramp supports multiple expansion catalysts.

AI summary

What happened, with direct paths to the underlying reporting

Celcuity received FDA approval for REVTORPYK in HR+/HER2- ABC without a PIK3CA mutation, with NCCN Category 1 guidance backing its use in second-line therapy. Positive VIKTORIA-1 MT data support a third-quarter 2026 sNDA and expansion into first-line settings via VIKTORIA-2. With $754m cash and a 2029 runway, plus $557.2m of net proceeds from convertible notes, Celcuity is financially positioned to execute a late-2026 commercial launch and drive early revenue growth.

  • FDA approves REVTORPYK (gedatolisib) for HR+/HER2- ABC without PIK3CA mutation; late-Q3 2026 launch.
  • NCCN Guidelines designate REVTORPYK with fulvestrant ± palbociclib as Category 1 for second-line use.
  • VIKTORIA-1 MT: PFS improvement; sNDA planned for Q3 2026; strong MT data.
  • VIKTORIA-2 expanded to first-line endocrine-sensitive HR+/HER2- ABC.
  • Celcuity raises $575m convertible notes; net $557.2m; cash runway to 2029.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event